Item 8.01. Other Events.

As previously disclosed, on December 16, 2022, Phoenix Biotech Acquisition Corp. (the "Company") held a special meeting of stockholders (the "Special Meeting") at 11:00 a.m. Eastern Time for the purposes of considering and voting upon, among other things, a proposal to amend its amended and restated certificate of incorporation (the "Charter Amendment") to extend the business combination deadline to April 8, 2023 and provide its board of directors the ability to further extend such deadline up to three additional times for one month each time, until a latest possible date of July 8, 2023. Such Charter Amendment was approved and was filed with the Secretary of State of the State of Delaware on December 20, 2022.

In connection with the approval of the Charter Amendment, holders of 16,211,702 shares of Class A common stock, par value $0.0001 per share ("Class A Shares") exercised redemption rights. As a result, following satisfaction of such redemptions, as of the date of this Current Report on Form 8-K, the Company has 2,173,298 Class A Shares outstanding, of which 1,288,298 are Class A Shares issued to the public in the Company's initial public offering, which Class A Shares are entitled to receive a pro rata portion of the remaining funds in the Company's trust account in connection with its initial business combination, a liquidation or certain other events, and 885,000 are Class A Shares included in the private placement units acquired in the private placement by Phoenix Biotech Sponsor, LLC ("Sponsor") and other investors concurrent with the Company's IPO, which Class A Shares do not have redemption rights.

On December 20, 2022, the Sponsor deposited $350,000 in the trust account in connection with the extension of the business combination deadline.

From December 28, 2022 through January 27, 2023, the Company withdrew approximately $16,000 to pay tax expenses and made a series of payments of an aggregate of $167,693,708.48 to holders of redeemed Class A Shares (an aggregate of $10.34 per redeemed Class A Share). As a result of the deposit described above, such payments and accrual of interest, the balance in the trust account as of the date of this Current Report on Form 8-K is approximately $13.8 million.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses